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Aims The associations between potassium level and outcomes, the effect of sacubitril–valsartan on potassium level, and
whether potassium level modified the effect of sacubitril–valsartan in patients with heart failure and a reduced ejection
fraction were studied in PARADIGM-HF. Several outcomes, including cardiovascular death, sudden death, pump failure
death, non-cardiovascular death and heart failure hospitalization, were examined.
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Methods
and results
A total of 8399 patients were randomized to either enalapril or sacubitril–valsartan. Potassium level at randomization
and follow-up was examined as a continuous and categorical variable (≤3.5, 3.6–4.0, 4.1–4.9, 5.0–5.4 and
≥5.5 mmol/L) in various statistical models. Hyperkalaemia was defined as K+ ≥5.5 mmol/L and hypokalaemia as
K+ ≤3.5 mmol/L. Compared with potassium 4.1–4.9 mmol/L, both hypokalaemia [hazard ratio (HR) 2.40, 95%
confidence interval (CI) 1.84–3.14] and hyperkalaemia (HR 1.42, 95% CI 1.10–1.83) were associated with a higher
risk for cardiovascular death. However, potassium abnormalities were similarly associated with sudden death and
pump failure death, as well as non-cardiovascular death and heart failure hospitalization. Sacubitril–valsartan had no
effect on potassium overall. The benefit of sacubitril–valsartan over enalapril was consistent across the range of
baseline potassium levels.
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Conclusions Although both higher and lower potassium levels were independent predictors of cardiovascular death, potassium
abnormalities may mainly be markers rather than mediators of risk for death.
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Introduction
Potassium is essential for normal cellular function and alterations
in its regulation can lead to gastrointestinal, neuromuscular and
cardiac abnormalities, some of which can be life-threatening.1
The treatments used in patients with heart failure and reduced
ejection fraction (HFrEF) commonly cause potassium disturbances;
hypokalaemia is induced by loop and thiazide diuretics, and hyper-
kalaemia results from the use of renin–angiotensin–aldosterone
system (RAAS) inhibitors.2,3 Although the clinical significance,
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. and even the definition, of hyperkalaemia is a matter of debate,
higher potassium concentrations often lead to the withholding
or withdrawal of RAAS inhibitors, which are life-saving thera-
pies in patients with HFrEF.4 However, hypokalaemia may be of
as much concern as hyperkalaemia in HFrEF because in other
groups of individuals (e.g. the general population and patients with
myocardial infarction, hypertension and chronic kidney disease5–9)
the relationship between potassium concentration and clinical
outcomes is U-shaped, and both low and high potassium levels are
associated with worse outcomes.10–12
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Serum potassium in PARADIGM-HF 2057
The effects of sacubitril–valsartan on potassium have not
been described in detail and may differ from those of enalapril
as sacubitril–valsartan reduces aldosterone, a key regulator
of potassium.13 The sacubitril–valsartan combination probably
lowers aldosterone because natriuretic peptides are power-
ful inhibitors of aldosterone secretion and neprilysin inhibition
(sacubitril) increases natriuretic peptide levels.14,15 The Prospec-
tive Comparison of ARNI with an ACE-Inhibitor to Determine
Impact on Global Mortality and Morbidity in Heart Failure trial
(PARADIGM-HF)13 represents one of the largest and most con-
temporary HFrEF cohorts, in which most patients received each
of the aforementioned drugs known to affect potassium levels.
The aims of the present study were to examine the range of
plasma potassium concentrations found in patients with HFrEF, the
relationships between potassium concentration and outcomes, and
the effect of sacubitril–valsartan on potassium.
Methods
PARADIGM-HF
The design, methods and principal results of the PARADIGM-HF trial
have been previously reported.13 In brief, the trial was a randomized,
double-blind, prospective comparison of the effect of sacubitril (97 mg)
and valsartan (103 mg) administered twice daily (LCZ696, 200 mg twice
daily) and that of enalapril (10 mg twice daily) in 8399 patients with
chronic HF [New York Heart Association (NYHA) classes II–IV] and a
left ventricular ejection fraction (LVEF) of ≤40%. Prior to randomiza-
tion, all participants underwent single-blind, sequential run-in periods
to ensure the tolerability of both study drugs at target doses. Eligi-
ble patients were those treated with an appropriate regimen of back-
ground HF medications at stable doses for at least 4 weeks, including
an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin
receptor blocker (ARB) (at a dose equivalent to enalapril 10 mg/day or
greater) and a beta-blocker (unless not tolerated). The use of miner-
alocorticoid receptor antagonists (MRAs) was left to the discretion
of the investigators but was encouraged if tolerated. Key exclusion
criteria included symptomatic hypotension, a systolic blood pressure
(SBP) of <100 mmHg at screening or 95 mmHg at randomization, an
estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m2 at
screening/randomization or a decrease in the eGFR of >25% (amended
to 35%) between screening and randomization, and a serum K+
level of >5.2 mmol/L at screening or >5.4 mmol/L at randomization.
Serum K+ was measured at every study visit (Supplementary mate-
rial online, Table S1). The protocol recommended that any patient
with serum potassium of >5.3 mmol/L after randomization required
regular, repeated checks of potassium concentration (beyond that pre-
scribed in the protocol) until it was clear that the potassium concen-
tration was stable and not rising to levels of concern (≥5.5 mmol/L and
<6.0 mmol/L) or potential danger (≥6.0 mmol/L).13 No recommenda-
tion for dose adjustment in the setting of hypokalaemia was given.
The primary composite endpoint was death from cardiovascular (CV)
causes or first hospitalization for HF (CV death/HF hospitalization).
The present analysis also examines CV, all-cause and sudden cardiac
death (or resuscitated cardiac arrest). The median follow-up time was
810 (range: 564–1069) days or 116 (range: 81–153) weeks. The trial
was approved by the institutional review board or ethics committee at
each participating site, and all participants provided written informed




















































































Continuous variables are expressed as the mean± standard devia-
tion or median (percentile25-75). Categorical variables are presented
as absolute numbers (n) and percentages. Baseline characteristics
were compared between the following K+ categories of ≤3.5, 3.6–4.0,
4.1–4.9, 5.0–5.4 and ≥5.5 mmol/L, using analysis of variance (ANOVA)
or Kruskal–Wallis tests as appropriate. Potassium levels below and
above the optimal range of 4–5 mmol/L were examined in order to
better elucidate which patient characteristics were associated with
‘non-optimal’ potassium concentrations and how clinical outcomes
related to potassium levels above and below the optimal range. The
additional categories created were ≤3.5 mmol/L and 3.6–4.0 mmol/L,
as well as 5.0–5.4 mmol/L and ≥5.5 mmol/L, as these included suf-
ficient numbers of patients and events to allow for valid statistical
analysis. Several models were used to study the association of K+ with
the outcomes. For baseline K+, Cox proportional hazards models
were used with K+ as a categorical or continuous variable (using a
fractional polynomial ‘spline’ with five knots as described by Harrell16).
For K+ throughout the follow-up, time-updated (‘repeated measures’)
Cox models were used with ‘start’ and ‘stop’ times between each K+
measurement. Multi-level survival analysis (a two-stage ‘joint model’)
was also used to combine the longitudinal (repeated-measures) and
survival (time-to-event endpoint) aspects of the data. A two-level
model with patient identification as a random effect and the log
(follow-up time) as a random coefficient was fitted. For the survival
portion of the model, a Weibull distribution was used, with the
continuous K+ (fractional polynomial) as the main exposure variable.
Landmark analyses were performed to assess the association between
the cumulative plus K+ changes at 2 months and subsequent outcomes.
The 2-month landmark was chosen to avoid excessive missing K+
values (Supplementary material online, Table S1). Regression estimates
are presented as hazard ratios (HR) with 95% confidence intervals
(CIs). The models were adjusted for all the characteristics presented in
Table 1, including age, diabetes, race, region, NYHA class, N-terminal
pro brain natriuretic peptide (NT-proBNP), concomitant medications
and eGFR (time-updated eGFR whenever appropriate). Potential
unmeasured confounding was examined by calculating E-values.17 All
statistical analyses were conducted in STATA® Version 16 (StataCorp
LP, College Station, TX, USA). A P-value of <0.05 was accepted as the
threshold for statistical significance without correction for multiplicity
of tests given the exploratory nature of this analysis.
Results
Baseline characteristics
The clinical characteristics of patients, according to serum
potassium category at randomization, are provided in Table 1.
Compared with patients with potassium within the normal range
(4.1–4.9 mmol/L), those with lower potassium levels were younger,
less often White, and had higher SBP and heart rate, better renal
function, higher NT-proBNP levels, a higher proportion of prior
HF hospitalization, and a lower proportion of treatment with an
ACEi/ARB and MRAs. In contrast, those with higher potassium
levels were more often White, were of similar age, had similar
SBP and heart rate, but had poorer renal function, slightly higher
NT-proBNP levels, and were more likely to have diabetes and to
be treated with ACEi/ARBs and MRAs (Table 1).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of PARADIGM-HF patients by potassium categories at randomization
Characteristics
by K+ categories
≤3.5 mmol/L 3.6–4.0 mmol/L 4.1–4.9 mmol/L 5.0–5.4 mmol/L ≥5.5 mmol/L P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n 164 1069 5625 1168 197
Age, years, mean± SD 62.0±13.0 61.7±12.2 63.9±11.3 65.4±10.7 63.4±10.8 <0.001
Age >70 years, n (%) 42 (25.6) 258 (24.1) 1704 (30.3) 400 (34.3) 58 (29.4) <0.001
Female sex, n (%) 39 (23.8) 251 (23.5) 1213 (21.6) 251 (21.5) 45 (22.8) 0.65
Race or ethnic group, n (%)
White 70 (42.7) 530 (49.6) 3796 (67.5) 858 (73.5) 150 (76.1) <0.001
Black 24 (14.6) 95 (8.9) 261 (4.6) 37 (3.2) 5 (2.5)
Asian 44 (26.8) 294 (27.5) 988 (17.6) 152 (13.0) 23 (11.7)
Other 26 (15.9) 150 (14.0) 580 (10.3) 121 (10.4) 19 (9.6)
Region, n (%)
North America 26 (15.9) 132 (12.3) 379 (6.7) 45 (3.9) 6 (3.0) <0.001
Latin America 33 (20.1) 227 (21.2) 928 (16.5) 188 (16.1) 32 (16.2)
Western Europe and other 36 (22.0) 179 (16.7) 1436 (25.5) 297 (25.4) 38 (19.3)
Central Europe 27 (16.5) 243 (22.7) 1906 (33.9) 490 (42.0) 97 (49.2)
Asia Pacific 42 (25.6) 288 (26.9) 976 (17.4) 148 (12.7) 24 (12.2)
Systolic blood pressure, mmHg,
mean± SD
125.0±17.0 122.5±16.1 121.3±15.3 120.1±14.4 119.9±13.3 <0.001
Heart rate, bpm, mean± SD 75.5±13.3 73.5±12.0 72.1±11.9 72.2±12.3 72.8±12.8 <0.001
BMI, kg/m2, mean± SD 28.2± 7.5 27.9± 5.8 28.2± 5.4 28.3± 5.4 28.0± 5.7 0.42
eGFR, mL/min/1.73 m2,
mean± SD
72.4± 34.1 72.4± 20.8 68.0±19.5 62.6±18.5 60.3±18.9 <0.001
eGFR ≤60, n (%) 62 (37.8) 312 (29.2) 2083 (37.0) 582 (49.8) 108 (54.8) <0.001
Ischaemic cardiomyopathy,
n (%)
90 (54.9) 588 (55.0) 3347 (59.5) 757 (64.8) 135 (68.5) <0.001
Left ventricular ejection
fraction, %, mean± SD
29.3± 6.4 29.4± 6.4 29.5± 6.2 29.6± 6.1 30.1± 6.4 0.59
BNP, pg/mL, median (range) 311 (184–717) 291 (169–611) 243 (150–447) 260 (160–468) 271 (171–530) <0.001
BNP in AF+, median (range) 360 (184–692) 291 (181–544) 245 (157–434) 251 (159–453) 273 (185–588) <0.001
BNP in AF-, median (range) 302 (183–783) 291 (161–643) 241 (145–455) 269 (160–471) 267 (153–491) <0.001
NT-proBNP, pg/mL, median
(range)
2476 (1199–5093) 1884 (941–4165) 1541 (862–3024) 1705 (946–3380) 1747 (926–3392) <0.001
NT-proBNP in AF+, median
(range)
3019 (1561–6083) 2131 (1114–4520) 1812 (1059–3420) 1961 (1172–3611) 2155 (1412–4781) <0.001
NT-proBNP in AF-, median
(range)
2276 (1090–4565) 1759 (847–3863) 1383 (804–2782) 1532 (856–3161) 1547 (747–2424) <0.001
NYHA functional class, n (%)
I 6 (3.7) 50 (4.7) 270 (4.8) 46 (4.0) 9 (4.6) 0.37
II 120 (73.2) 774 (72.5) 3971 (70.7) 801 (68.8) 131 (67.2)
III 36 (22.0) 235 (22.0) 1342 (23.9) 306 (26.3) 55 (28.2)
IV 2 (1.2) 9 (0.8) 36 (0.6) 11 (0.9) 0 (0.0)
Hypertension, n (%) 116 (70.7) 758 (70.9) 3928 (69.8) 866 (74.1) 140 (71.1) 0.068
Diabetes, n (%) 54 (32.9) 334 (31.2) 1915 (34.0) 458 (39.2) 79 (40.1) <0.001
Atrial fibrillation, n (%) 60 (36.6) 360 (33.7) 2075 (36.9) 445 (38.1) 82 (41.6) 0.12
Prior HF hospitalization, n (%) 119 (72.6) 669 (62.6) 3542 (63.0) 715 (61.2) 119 (60.4) 0.074
Prior MI, n (%) 61 (37.2) 411 (38.4) 2420 (43.0) 554 (47.4) 99 (50.3) <0.001
Prior stroke, n (%) 15 (9.1) 77 (7.2) 509 (9.0) 95 (8.1) 11 (5.6) 0.15
Prior use of ACEi, n (%) 115 (70.1) 772 (72.2) 4395 (78.1) 945 (80.9) 162 (82.2) <0.001
Prior use of ARB, n (%) 51 (31.1) 298 (27.9) 1249 (22.2) 225 (19.3) 36 (18.3) <0.001
Diuretic, n (%) 141 (86.0) 892 (83.4) 4482 (79.7) 920 (78.8) 156 (79.2) 0.011
Digoxin, n (%) 50 (30.5) 334 (31.2) 1718 (30.5) 341 (29.2) 57 (28.9) 0.84
Beta-blocker, n (%) 154 (93.9) 968 (90.6) 5247 (93.3) 1098 (94.0) 182 (92.4) 0.013
MRA, n (%) 75 (45.7) 509 (47.6) 3179 (56.5) 704 (60.3) 117 (59.4) <0.001
ICD (incl. CRT-D), n (%) 18 (11.0) 139 (13.0) 868 (15.4) 176 (15.1) 18 (9.1) 0.022
CRT, n (%) 9 (5.5) 66 (6.2) 398 (7.1) 83 (7.1) 9 (4.6) 0.49
Randomized to
sacubitril–valsartan, n (%)
84 (51.2) 527 (49.3) 2787 (49.5) 605 (51.8) 94 (47.7) 0.63
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; CRT, cardiac resynchronization therapy;
eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal
pro brain natriuretic peptide; SD, standard deviation.
Change in potassium level
A median of 8.5 (range: 1–16) central laboratory potassium
measurements were performed per patient after randomization,
averaging 13.6 measurements per year of follow-up. During the







.. (39 699 in the enalapril group and 39 989 in the sacubitril–valsartan
group); there were 8473 occasions (10.6% of all occasions)
when potassium was <4 mmol/L and 1601 (2.0%) occasions when
potassium was ≤3.5 mmol/L. A potassium value of <4 mmol/L
was observed on 3942 (9.9%) occasions in the enalapril group
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Proportion of occasions/visits in which an abnormal value of potassium was detected separated by treatment group. Sac/Val,
sacubitril–valsartan.
and on 4531 (11.3%) occasions in the sacubitril–valsartan group
(sacubitril–valsartan vs. enalapril, P < 0.001). A potassium level of
<3.5 mmol/L was observed on 722 (1.8%) occasions in the enalapril
group and 879 (2.2%) occasions in the sacubitril–valsartan group
(sacubitril–valsartan vs. enalapril, P < 0.001). During the follow-up,
a potassium level of >5 mmol/L was observed on 5368 (13.5%)
occasions in the enalapril group and 4915 (12.3%) occasions in
the sacubitril–valsartan group (sacubitril–valsartan vs. enalapril,
P < 0.001). A potassium level of >5.5 mmol/L was observed on
974 (2.5%) occasions in the enalapril group and on 896 (2.2%)
occasions in the sacubitril–valsartan group (sacubitril–valsartan
vs. enalapril, P = 0.047) (Figure 1). Supplementary material online,
Figure S1 presents the incidences of both hypo- and hyperkalaemia
over time by treatment group.
Compared with enalapril, sacubitril–valsartan reduced potas-
sium concentration slightly [mean change, compared with enalapril,
at week 80: −0.07 mmol/L (range: −0.09 to −0.04 mmol/L);
P < 0.001].
Patients treated with enalapril and an MRA had slightly higher
potassium levels than patients treated with sacubitril–valsartan and
an MRA. Patients treated with sacubitril–valsartan and an MRA




There was a U-shaped relationship between baseline potassium
level and the clinical outcomes of interest. Patients in the lowest
baseline potassium category (≤3.5 mmol/L) had higher event rates
in comparison with patients with potassium in the normal range
(4.1–4.9 mmol/L), even after adjustment for other prognostic
variables (Table 2). This was also true for those in the highest
potassium category (≥5.5 mmol/L) in relation to the mortality
outcomes, although the magnitude of the elevation in risk was























































Figure 2 Potassium levels in patients allocated to
sacubitril–valsartan or enalapril with or without a miner-
alocorticoid receptor antagonist (MRA). K+ change at week 80
sacubitril–valsartan vs. enalapril and no MRA: −0.05 (−0.08 to
−0.01), P = 0.007. K+ change at week 80 sacubitril–valsartan vs.
enalapril and MRA: −0.08 (−0.11 to −0.04), P < 0.001. Sac/Val,
sacubitril–valsartan.
This overall pattern was generally more pronounced in the
time-updated models. For the primary outcome, the HR for a
potassium level of 3.6–4.0 mmol/L was 1.25 (95% CI 1.06–1.47)
and the HR for a potassium concentration of ≤3.5 mmol/L was
1.91 (95% CI 1.41–2.61), compared with the reference category
(potassium 4.1–4.9 mmol/L). The HR for a potassium level of
5.0–5.4 mmol/L was 1.08 (95% CI 0.92–1.27) and for a potassium
level of ≥5.5 mmol/L was 1.38 (95% CI 1.06–1.78).
Similar results were obtained for the individual components of
the primary outcome and all-cause death. The associations for
sudden death and pump failure death were statistically significant
for potassium levels of ≤3.5 mmol/L. Non-CV death also appeared
to show a U-shaped association with potassium, but this was not
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Baseline model P-value Time-updated
model
P-value K+ by study drug
interaction P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary outcome
≤3.5 70 (42.7) 24.8 1.86 (1.46–2.37) <0.001 1.91 (1.41–2.61) <0.001 0.20
3.6–4.0 303 (28.3) 14.1 1.25 (1.10–1.42) 0.001 1.25 (1.06–1.47) 0.009
4.1–4.9 1277 (22.7) 11 Referent – Referent –
5.0–5.4 292 (25.0) 12.3 1.08 (0.95–1.23) 0.25 1.08 (0.92–1.27) 0.35
≥5.5 47 (23.9) 12.7 1.11 (0.83–1.48) 0.50 1.38 (1.06–1.78) 0.015
HF hospitalization
≤3.5 40 (24.4) 14.2 1.79 (1.29–2.47) <0.001 2.01 (1.14–3.55) 0.016 0.55
3.6–4.0 192 (18.0) 8.9 1.39 (1.18–1.63) <0.001 1.32 (9.98–1.77) 0.063
4.1–4.9 741 (13.2) 6.4 Referent – Referent –
5.0–5.4 173 (14.8) 7.3 1.08 (0.92–1.28) 0.34 1.35 (1.03–1.77) 0.028
≥5.5 21 (10.7) 5.7 0.85 (0.55–1.31) 0.45 1.02 (0.50–1.08) 0.95
CV death
≤3.5 52 (31.7) 16.1 2.25 (1.69–2.99) <0.001 2.40 (1.84–3.14) <0.001 0.45
3.6–4.0 177 (16.6) 7.4 1.14 (0.97–1.35) 0.11 1.27 (1.07–1.49) 0.005
4.1–4.9 778 (13.8) 6.2 Referent – Referent –
5.0–5.4 186 (15.9) 7.3 1.13 (0.97–1.34) 0.11 1.19 (1.02–1.40) 0.029
≥5.5 37 (18.8) 9.6 1.48 (1.06–2.06) 0.021 1.42 (1.10–1.83) 0.007
All-cause death
≤3.5 57 (34.8) 17.6 2.00 (1.51–2.62) <0.001 2.31 (1.80–2.96) <0.001 0.41
3.6–4.0 215 (20.1) 9 1.14 (0.98–1.33) 0.084 1.26 (1.09–1.47) 0.002
4.1–4.9 963 (17.1) 7.7 Referent – Referent –
5.0–5.4 235 (20.1) 9.2 1.15 (1.00–1.33) 0.052 1.26 (1.09–1.44) 0.001
≥5.5 47 (23.9) 12.2 1.51 (1.12–2.02) 0.006 1.37 (1.09–1.73) 0.007
SCD or RCA
≤3.5 21 (12.8) 6.5 1.73 (1.11–2.70) 0.015 2.45 (1.70–3.54) <0.001 0.064
3.6–4.0 75 (7.0) 3.1 0.90 (0.70–1.15) 0.39 1.20 (0.95–1.52) 0.13
4.1–4.9 399 (7.1) 3.2 Referent – Referent –
5.0–5.4 82 (7.0) 3.2 1.03 (0.81–1.31) 0.81 1.41 (1.13–1.75) 0.002
≥5.5 20 (10.2) 5.3 1.65 (1.05–2.59) 0.03 1.01 (0.64–1.59) 0.97
Pump failure death
≤3.5 15 (9.2) 4.6 2.75 (1.61–4.70) <0.001 3.43 (2.15–5.48) <0.001 0.26
3.6–4.0 56 (5.2) 2.3 1.54 (1.13–2.08) 0.006 1.33 (0.96–1.85) 0.087
4.1–4.9 194 (3.5) 1.6 Referent – Referent –
5.0–5.4 51 (4.4) 2.0 1.18 (0.87–1.61) 0.29 1.22 (0.91–1.65) 0.19
≥5.5 10 (5.1) 2.6 1.54 (0.81–2.92) 0.18 1.49 (0.93–1.37) 0.095
Non-CV death
≤3.5 5 (3.1) 1.5 0.83 (0.30–2.24) 0.71 1.86 (0.95–3.66) 0.072 0.46
3.6–4.0 38 (3.6) 1.6 1.15 (0.80–1.64) 0.45 1.24 (0.87–1.77) 0.23
4.1–4.9 185 (3.3) 1.5 Referent – Referent –
5.0–5.4 49 (4.2) 1.9 1.22 (0.88–1.67) 0.23 1.54 (1.15–2.08) 0.004
≥5.5 10 (5.1) 2.6 1.66 (0.87–3.15) 0.12 1.17 (0.66–2.07) 0.59
All models are adjusted on age, sex, race, region, systolic blood pressure, heart rate, body mass index, estimated glomerular filtration rate, ischaemic cardiomyopathy, left
ventricular ejection fraction, N-terminal pro brain natriuretic peptide, New York Heart Association class, hypertension, diabetes, atrial fibrillation, prior HF hospitalization,
prior myocardial infarction, prior stroke, use of diuretics, digoxin, beta-blockers, MRAs, cardiac devices, and treatment group allocation (sacubitril–valsartan or enalapril).
CV, cardiovascular; HF, heart failure; MRA, mineralocorticoid receptor antagonist; RCA, resuscitated cardiac arrest; SCD, sudden cardiac death or pump failure death.
The K+ group by study drug interaction P-value refers to the interaction between the time-updated potassium levels and the study drug (sacubitril–valsartan or enalapril).
The interaction between the time-updated potassium levels and eGFR (≤60 vs. >60 mL/min/1.73 m2) was also tested and none was significant (interaction P ≥ 0.1 for all the
studied outcomes).
statistically significant for potassium levels of either ≤3.5 mmol/L
or ≥5.5 mmol/L, possibly as a result of the small number of events
(Table 2).
The associations between time-updated potassium level, mod-







. shown in Figure 3 and reinforce the findings of the categorical anal-
yses described above. The same is shown for baseline potassium
in supplementary material online, Figure S2. The landmark analysis
and joint models are illustrated in supplementary material online,
Figures S3 and S4. To offset the association between hypokalaemia
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Figure 3 Time-updated potassium and associations with the studied outcomes. The primary outcome was a composite of cardiovascular
(CV) death or heart failure (HF) hospitalization. CI, confidence interval; HR, hazard ratio.
(≤3.5 mmol/L) and risk for the primary outcome, an ‘unmeasured’
confounder would need to have an incremental HR of ≥2.5 on top
of the adjusted analysis described (Supplementary material online,
Figure S5).
Outcomes related to change
in potassium category
Landmark analysis, looking at outcomes according to change in
potassium category, showed that patients moving from either the
lowest or highest potassium category to the normal category
had better outcomes than those remaining in the two extreme


















.. the persistence of either hypokalaemia or hyperkalaemia was
associated with a higher risk for subsequent CV death [HR 1.61
(95% CI 1.25–2.09), P < 0.001 for persistence of hypokalaemia;
HR 1.32 (95% CI 1.01–1.72), P = 0.041 for persistence of
hyperkalaemia].
Effect of sacubitril–valsartan according
to potassium level
The benefit of sacubitril–valsartan over enalapril was consistent
across baseline potassium categories and using potassium as a
continuous time-updated variable (Figure 4).
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Figure 4 Interaction between serum potassium levels and the
study treatment. (A) Serum potassium (time-updated, continuous)
by study treatment. (B) Treatment effect throughout the spectrum
of potassium concentration. Example illustrating the primary
outcome associations (similar results are obtained for the other
outcomes) i.e. no potassium by study treatment interaction (see
also Table 2). CI, confidence interval; HR, hazard ratio; TTx effect,
treatment effect of sacubitril–valsartan vs. enalapril.
Discussion
The present study found that both hypo- and hyperkalaemia were
associated with a higher risk for adverse clinical outcomes, com-
pared with a normal potassium concentration. Although the risk
was greater with hypokalaemia than with hyperkalaemia, the asso-
ciations were largely non-specific, suggesting that the risk related
to potassium disturbances reflected disease severity, rather than a
direct effect of potassium. Sacubitril–valsartan reduced potassium
level slightly, on average, compared with enalapril. The beneficial
effect of sacubitril–valsartan over enalapril was consistent across
the spectrum of potassium levels studied in PARADIGM-HF.
In keeping with prior studies in patients recently discharged after
hospital admission for HF and in chronic HFrEF, the present study
found a U-shaped relationship between potassium level and mortal-
ity in the well-treated ambulatory patients with chronic HFrEF and
mainly mild symptoms in PARADIGM-HF.18–21 After adjusting for



















































































.. in risk for death associated with higher potassium was modest and
less pronounced than in hypokalaemia. Although prior studies have
suggested that the elevated risk for death associated with hyper-
kalaemia may reflect underdosing or even the withholding of RAAS
blockers,22,23 this is not likely to represent the explanation in the
present trial given that patients started on the maximum dose of
the study drug and every effort was made to maintain the optimal
dose during follow-up. Moreover, the associations between higher
potassium and fatal outcomes were similar for all subtypes of death
examined, including non-CV death, which suggests a lack of any
specific mechanistic direct effect of hyperkalaemia. This perspec-
tive is supported by the similar association between hyperkalaemia
and risk for HF hospitalization, given the lack of obvious patho-
physiological link between higher potassium and risk for HF hos-
pitalization. Scrutiny of the baseline characteristics of participants
with hyperkalaemia shows them to be older, to have more frequent
ischaemic aetiology and greater comorbidity, including worse renal
function. It is possible that the multivariable models used in the
present study did not fully adjust for the measured and unmeasured
differences between patients with hyperkalaemia and those with
normal potassium levels. Therefore, a higher potassium concentra-
tion may generally represent a marker of a sicker patient, although,
in individuals, occasionally, hyperkalaemia may still directly cause a
fatal arrhythmia or conduction disturbance.24–26
There was also an association between low potassium and higher
mortality and the risk associated with low potassium was greater
than that found for high potassium and was strengthened in the
time-updated model. Although all patients were on a full dose
of enalapril or sacubitril–valsartan, MRA use was less frequent
in individuals in the lowest potassium category, in contrast to
those with high potassium concentrations. However, MRA use was
included in the multivariable adjustment and therefore neither the
lower use of MRAs nor the underuse of ACEi or ARBs seem
to account for the association between hypokalaemia and higher
risk for death. More surprisingly, perhaps, the association between
low potassium and outcomes also appeared to lack specificity,
with similarly elevated risk for various types of death, as seen
with higher potassium concentrations. Moreover, the risk for HF
hospitalization was elevated to the same degree as that for overall
and cause-specific mortality. This suggests that the association
between hypokalaemia and worse outcomes is non-specific in
nature and low potassium may also be a marker of disease severity.
At first sight, this conclusion may seem to be at variance with the
finding that the ‘correction’ of hypokalaemia (and hyperkalaemia)
was associated with a better outcome than a persisting abnormality
of potassium. However, the patients who shifted from an abnormal
to a normal potassium category may have been patients whose
clinical status improved.
Another interesting observation was that the overall comorbid-
ity profile of patients with hypokalaemia was generally of lower
risk than that of patients with hyperkalaemia; patients in the lower
potassium categories had better renal function, and less ischaemic
cardiac disease, diabetes and atrial fibrillation than patients with
higher potassium, although patients with low potassium had higher
NT-proBNP levels, greater use of diuretics and a more frequent
history of HF hospitalization. One interpretation of these findings
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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may be that low potassium, reflecting a greater use of diuretics
and less use of MRAs in more recently hospitalized and inade-
quately decongested patients, is a marker of a patient with a greater
probability of worsening that will lead to hospital admission or
death.27 This might suggest that the present multivariable adjust-
ment did not fully account for some of the measured confounders
discussed or that there was significant unmeasured confounding.
For example, there were striking differences in geographic region
of enrolment and race across potassium categories. North America
(a region of low MRA use) was relatively over-represented and
Central and Eastern Europe (regions of high MRA use) were rel-
atively under-represented in the potassium ≤3.5 mmol/L category,
although there are clearly many other demographic, social, cul-
tural and environmental influences on health, and differences in
health care provision, across these regions. There was also rela-
tive over-representation of Black and Asian individuals in the low-
est potassium category, compared with the normal and higher
potassium groups. The explanation for this is not obvious. The
use of MRAs was not lower in Blacks or Asians and the other
factors mentioned in relation to geographical region plus addi-
tional genetic variables may be important.28 Finally, it remains likely
that a general indirect and non-specific association between lower
potassium level and worse outcome, as discussed, conceals a true
direct biological link, at least in some patients, between profound
hypokalaemia and cardiac mortality.
Compared with enalapril, sacubitril–valsartan had little effect
on potassium in PARADIGM-HF, overall. However, in participants
treated with an MRA, compared with enalapril, sacubitril–valsartan
reduced potassium significantly, maintaining levels within the nor-
mal range (and similar to those in patients not treated with
MRAs).29 One possible (but merely speculative) explanation for
the lower potassium levels in the sacubitril–valsartan group is
that compared with enalapril, sacubitril–valsartan improved renal
function and this may have led to greater distal delivery of loop
diuretic and more potassium excretion as a result. A previ-
ous report demonstrated that sacubitril–valsartan reduced the
risk for hyperkalaemia in patients treated with an MRA.30 The
present study expands those findings by comparing the effects of
sacubitril–valsartan with those of enalapril across the full spec-
trum of potassium concentrations. Furthermore, the benefit of
sacubitril–valsartan over enalapril was consistent across the range
of baseline potassium levels among the patients randomized in
PARADIGM-HF.
Limitations
This was a post hoc analysis of the PARADIGM-HF trial. The
patients were highly selected, tolerating recommended doses of
enalapril and sacubitril–valsartan in a run-in period. Although this
reduces the generalizability of the current findings, the trial design
also addresses the limitations of earlier studies. Regular monitoring
of potassium and protocol-guided mitigation may have led to the
correction of potassium abnormalities more frequently, or more
quickly, than in routine practice (and perhaps in hyperkalaemia
more often than in hypokalaemia, as treatment of only the former



















































































.. of >5.2 mmol/L at screening (or >5.4 mmol/L at randomization)
was an exclusion criterion, which may have led to the selection of
patients less prone to the development of hyperkalaemia. Although
having an independent adjudication committee was a major advan-
tage of the present study, some events, including sudden death and
pump failure death, remain difficult to adjudicate and may be prone
to misclassification.
Conclusions
In PARADIGM-HF, both hyperkalaemia and hypokalaemia were
associated with a higher risk for death, although the associa-
tion was stronger for the latter. While both higher and lower
potassium levels remained independent predictors of death after
adjustment in multivariable models, they were also associated with
non-CV death and HF hospitalization, which suggests that potas-
sium abnormalities are mainly markers of disease severity. Com-
pared with enalapril, sacubitril–valsartan had no overall effect on
potassium concentrations in PARADIGM-HF, although it reduced
potassium significantly in participants treated with an MRA, main-
taining it in the normal range in these individuals. The benefit of
sacubitril–valsartan over enalapril was consistent across the range
of baseline potassium levels among the patients randomized in
PARADIGM-HF.
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Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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